Skip to main content
. Author manuscript; available in PMC: 2021 Oct 8.
Published in final edited form as: Nat Immunol. 2021 Apr 8;22(5):607–619. doi: 10.1038/s41590-021-00910-8

Figure 8: IL2 therapy mitigates Foxp3 deficiency disease.

Figure 8:

a. IL2 treatment protocol: daily injection of IL2/αIL2 complex for three consecutive days every week starting 11 days after birth.

b. Body weight index growth curves of vehicle (PBS) and IL2 (IL2/αIL2) treated ΔFoxp3 mice (mean +/− SEM). * One-way ANOVA p < 0.05 (b), n = 10 and 19 (PBS and IL2 groups, respectively)

c. Survival curves of vehicle (PBS) and IL2 (IL2/αIL2) treated ΔFoxp3 mice ** Log Rank test p < 10–4, n = 24 and 15 (PBS and IL2 groups, respectively)

d. Proportion of CD25+GFP+ Tregs cells in vehicle (PBS) and IL2 (IL2/αIL2) treated ΔFoxp3 mice (day 22). Right: Representative flow cytometric CD25/GFP plots of CD4+ T cells. **** two-sided t.test p < 10–4, n = 14 and 13 (PBS and IL2 groups, respectively)